Intra-Cellular Therapies, Inc. with ticker code (ITCI) have now 15 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $101.00 and $65.00 and has a mean share price target at $83.77. (at the time of writing). Now with the previous closing price of $67.21 this would indicate that there is a potential upside of 24.6%. The 50 day moving average now sits at $68.85 while the 200 day moving average is $61.65. The market cap for the company is 6.54B. The current share price for the company is: $67.59 USD
The potential market cap would be $8,155,389,286 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $4.84 and a -13.43% return on assets.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled bipolar depression studies, which evaluated the effects of CAPLYTA on depression in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study 404) and as adjunctive therapy with lithium or valproate (Study 402).
